2014 Fiscal Year Final Research Report
New therapeutic strategy targeting CD44 against urothelial cancer
| Project/Area Number |
25861454
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | 尿路上皮癌 / 癌幹細胞 |
|---|
| Outline of Final Research Achievements |
We examined the immunohistochemical experession of CD44v in urothelial cancer (UC) and analyzed its clinical significance in patients treated with nephroureterectomy for invasive UC. Multivariate analysis showed that CD44v expression was the independent risk factors for cancer-specific mortality. Metformin markedly reduced the viability of the highly CD44v-expressing T24 cells in a dose-dependent manner.Cell growth inhibition was significantly higher in the combination therapy compared to metformin or cisplatin alone in T24 cells. Flow cytometry revealed that metformin selectively reduced the proportion of highly CD44v-expressing tumor cells. Combination therapy showed marked suppression of tumor growth compared with control, and metformin and CDDP monotherapy groups in xenograft model.
|
| Free Research Field |
尿路上皮癌
|
